Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook
Q4 2023 revenue $26.5 million and FY 2023 revenue $96.6 millionGuiding FY 2024 revenue range $114.0-118.0 million and operating cash […]
Pool Corporation to Participate in the Loop Capital Markets 2024 Investor Conference
COVINGTON, La., March 04, 2024 (GLOBE NEWSWIRE) — Pool Corporation (Nasdaq:POOL) announced today that Melanie M. Hart, Vice President and […]
OrthoPediatrics Corp. Launches New RESPONSE Rib and Pelvic Fixation System for EOS Scoliosis
WARSAW, Ind., March 04, 2024 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS a company focused exclusively […]
Nasdaq February 2024 Volumes
NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today reported monthly volumes for February 2024 on its […]
Rigetti Computing to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 14, 2024
BERKELEY, Calif., March 04, 2024 (GLOBE NEWSWIRE) — Rigetti Computing, Inc. (“Rigetti” or the “Company”) (Nasdaq: RGTI), a pioneer in […]
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
ROCKVILLE, Md., March 04, 2024 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing […]
Singular Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) — Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing […]
Stereotaxis Reports 2023 Full Year Financial Results
ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for […]
Enovix to Present at J.P. Morgan Industrials Conference
FREMONT, Calif., March 04, 2024 (GLOBE NEWSWIRE) — Enovix Corporation (“Enovix”) (Nasdaq: ENVX), an advanced silicon battery company, today announced […]
Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
SAN FRANCISCO and WALTHAM, Mass., March 04, 2024 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company […]
